Cargando…

Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms

Cardiovascular disease (CVDs) is the first killer of human health, and it caused up at least 31% of global deaths. Atherosclerosis is one of the main reasons caused CVDs. Oral drug therapy with statins and other lipid-regulating drugs is the conventional treatment strategies for atherosclerosis. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Ting, Zhang, Zhen, Xu, Junbo, Liu, Hanxiong, Cai, Lin, Huang, Gang, Wang, Chunbin, Chen, Yingzhong, Xia, Long, Ding, Xunshi, Wang, Jin, Li, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315585/
https://www.ncbi.nlm.nih.gov/pubmed/37404681
http://dx.doi.org/10.3389/fbioe.2023.1205751
_version_ 1785067533509853184
author Luo, Ting
Zhang, Zhen
Xu, Junbo
Liu, Hanxiong
Cai, Lin
Huang, Gang
Wang, Chunbin
Chen, Yingzhong
Xia, Long
Ding, Xunshi
Wang, Jin
Li, Xin
author_facet Luo, Ting
Zhang, Zhen
Xu, Junbo
Liu, Hanxiong
Cai, Lin
Huang, Gang
Wang, Chunbin
Chen, Yingzhong
Xia, Long
Ding, Xunshi
Wang, Jin
Li, Xin
author_sort Luo, Ting
collection PubMed
description Cardiovascular disease (CVDs) is the first killer of human health, and it caused up at least 31% of global deaths. Atherosclerosis is one of the main reasons caused CVDs. Oral drug therapy with statins and other lipid-regulating drugs is the conventional treatment strategies for atherosclerosis. However, conventional therapeutic strategies are constrained by low drug utilization and non-target organ injury problems. Micro-nano materials, including particles, liposomes, micelles and bubbles, have been developed as the revolutionized tools for CVDs detection and drug delivery, specifically atherosclerotic targeting treatment. Furthermore, the micro-nano materials also could be designed to intelligently and responsive targeting drug delivering, and then become a promising tool to achieve atherosclerosis precision treatment. This work reviewed the advances in atherosclerosis nanotherapy, including the materials carriers, target sites, responsive model and treatment results. These nanoagents precisely delivery the therapeutic agents to the target atherosclerosis sites, and intelligent and precise release of drugs, which could minimize the potential adverse effects and be more effective in atherosclerosis lesion.
format Online
Article
Text
id pubmed-10315585
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103155852023-07-04 Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms Luo, Ting Zhang, Zhen Xu, Junbo Liu, Hanxiong Cai, Lin Huang, Gang Wang, Chunbin Chen, Yingzhong Xia, Long Ding, Xunshi Wang, Jin Li, Xin Front Bioeng Biotechnol Bioengineering and Biotechnology Cardiovascular disease (CVDs) is the first killer of human health, and it caused up at least 31% of global deaths. Atherosclerosis is one of the main reasons caused CVDs. Oral drug therapy with statins and other lipid-regulating drugs is the conventional treatment strategies for atherosclerosis. However, conventional therapeutic strategies are constrained by low drug utilization and non-target organ injury problems. Micro-nano materials, including particles, liposomes, micelles and bubbles, have been developed as the revolutionized tools for CVDs detection and drug delivery, specifically atherosclerotic targeting treatment. Furthermore, the micro-nano materials also could be designed to intelligently and responsive targeting drug delivering, and then become a promising tool to achieve atherosclerosis precision treatment. This work reviewed the advances in atherosclerosis nanotherapy, including the materials carriers, target sites, responsive model and treatment results. These nanoagents precisely delivery the therapeutic agents to the target atherosclerosis sites, and intelligent and precise release of drugs, which could minimize the potential adverse effects and be more effective in atherosclerosis lesion. Frontiers Media S.A. 2023-06-19 /pmc/articles/PMC10315585/ /pubmed/37404681 http://dx.doi.org/10.3389/fbioe.2023.1205751 Text en Copyright © 2023 Luo, Zhang, Xu, Liu, Cai, Huang, Wang, Chen, Xia, Ding, Wang and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Luo, Ting
Zhang, Zhen
Xu, Junbo
Liu, Hanxiong
Cai, Lin
Huang, Gang
Wang, Chunbin
Chen, Yingzhong
Xia, Long
Ding, Xunshi
Wang, Jin
Li, Xin
Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms
title Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms
title_full Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms
title_fullStr Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms
title_full_unstemmed Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms
title_short Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms
title_sort atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315585/
https://www.ncbi.nlm.nih.gov/pubmed/37404681
http://dx.doi.org/10.3389/fbioe.2023.1205751
work_keys_str_mv AT luoting atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms
AT zhangzhen atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms
AT xujunbo atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms
AT liuhanxiong atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms
AT cailin atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms
AT huanggang atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms
AT wangchunbin atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms
AT chenyingzhong atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms
AT xialong atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms
AT dingxunshi atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms
AT wangjin atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms
AT lixin atherosclerosistreatmentwithnanoagentpotentialtargetsstimulussignalsanddrugdeliverymechanisms